Efalizumab, a reversible T-cell modulator for psoriasis

Journal of Cutaneous Medicine and Surgery

Volumn 9, Issue SUPPL. 1, 2005, Pages 4-9

  Shear, Neil H ^a,d   Langley, Richard G ^b   Ho, Vincent ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; CD8 ANTIGEN; EFALIZUMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

CD8+ T LYMPHOCYTE; CELL INTERACTION; CELL SURFACE; CELL TYPE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; INFLAMMATION; LYSOSOME; MEMORY CELL; PRIORITY JOURNAL; PSORIASIS; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 33747336798     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-006-0101-3     Document Type: Review

References (28)

1. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113:1664-1675.
2. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139:846-850.
3. Walsh SRA, Shear NH. Psoriasis and the new biologic agents: interrupting a T-AP dance. CMAJ 2004; 170:1933-1941.
4. Langley RG, Ho V, Lynde C, et al. Recommendations for incorporating biologicals into management of moderate-to-severe plaque psoriasis: individualized patient approaches. J Cutan Med Surg 2005; This supplement.
5. Vugmeyster Y, Kikuchi T, Lowes MA, et al. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8 + T cells into lesional skin. Clin Immunol 2004; 113:38-46.
6. Coffey GP, Fox JA, Pippig S, et al. Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 2005; 33:623-629.
7. Willenborg DO, Staykova MA, Miyasaka M. Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. J Immunol 1996; 157:1973-1980.
8. Papp K. Patient management in psoriasis treatment using efalizumab. J Cutan Med Surg 2005; This supplement.
9. Jullien D, Prinz JC, Langley RG, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004; 208:297-306.
10. Ovigne JM, Baker BS, Davison SC, et al. Epidermal CD8 + T cells reactive with group A streptococcal antigens in chronic plaque psoriasis. Exp Dermatol 2002; 11:357-364.
11. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999; 155:145-158.
12. Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17:257-270.
13. Anderson ME, Siahaan TJ. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 2003; 24:487-501.
14. Shang XZ, Lang BJ, Issekutz AC. Adhesion molecule mechanisms mediating monocyte migration through synovial fibroblast and endothelium barriers: role for CD11/CD18, very late antigen-4 (CD49d/CD29), very late antigen-5 (CD49e/CD29), and vascular cell adhesion molecule-1 (CD106). J Immunol 1998; 160:467-474.
15. Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002; 138:591-600.
16. Mortensen DL, Walicke PA, Wang X, et al. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 2005; 45:286-298.
17. Deguchi M, Aiba S, Ohtani H, et al. Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocytemediated dermatoses: CD1a +, Factor XIIIa +, and CD68 + cells in eczematous dermatitis, psoriasis, lichen planus and graft-versushost disease. Arch Dermatol Res 2002; 294:297-302.
18. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20:40-46.
19. Bruynzeel I, Koopman G, Raaij LMvan der, et al. CD44 antibody stimulates adhesion of peripheral blood T cells to keratinocytes through the leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J Invest Dermatol 1993; 100:424-428.
20. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996; 157:4986-4965.
21. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64 Suppl 2:ii30-36.
22. Coffey GP, Stefanich E, Palmieri S, et al. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Ther 2004; 310:896-904.
23. Sun YN, Lu JF, Joshi A, et al. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 2005; 45:468-476.
24. Bauer RJ, Dedrick RL, White ML, et al. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 1999; 27:397-420.
25. Raptiva® (efalizumab) US Prescribing Information. Genentech, Inc. 2005.
26. Raptiva® (efalizumab) Canadian Prescribing Information. Serono Canada, Inc. 2005.
27. Wellington K, Perry CM. Efalizumab. Am J Clin Dermatol 2005; 6:113-118.
28. Poulin Y, Papp KA, Carey W, Gulliver W. Efalizumab for longterm control of moderate-to-severe psoriasis. J Cutan Med Surg 2005; This supplement.